Literature DB >> 11903612

Immunopathogenesis of hepatitis C virus infection.

A J Freeman1, G Marinos, R A Ffrench, A R Lloyd.   

Abstract

Hepatitis C virus, a recently identified member of the family Flaviviridae, is an important cause of chronic viral hepatitis and cirrhosis. There are similarities in the nature of the immune response to this pathogen with immunity in other flavivirus and hepatotropic virus infections, such as hepatitis B. However, the high rate of viral persistence after primary hepatitis C infection, and the observation that neutralizing antibodies are not protective, would suggest that there are a number of important differences between hepatitis C, other flaviviruses, and hepatitis B. The phenomenon of quasispecies evolution and other viral factors have been proposed to contribute to immune evasion by hepatitis C virus. In the face of established persistent infection, virus-specific cytotoxic T lymphocytes may exert some control over viral replication. However, these same effectors may also be responsible for the progressive liver damage characteristic of chronic hepatitis C infection. The nature of protective immunity, including the role of innate immune responses early after hepatitis C exposure, remains to be defined.

Entities:  

Mesh:

Year:  2001        PMID: 11903612     DOI: 10.1046/j.1440-1711.2001.01036.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  28 in total

1.  High-affinity aptamers to subtype 3a hepatitis C virus polymerase display genotypic specificity.

Authors:  Louisa A Jones; Leighton E Clancy; William D Rawlinson; Peter A White
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Characterization of HCV-specific CD4+Th17 immunity in recurrent hepatitis C-induced liver allograft fibrosis.

Authors:  H I Basha; V Subramanian; A Seetharam; D S Nath; S Ramachandran; C D Anderson; S Shenoy; W C Chapman; J S Crippin; T Mohanakumar
Journal:  Am J Transplant       Date:  2011-04       Impact factor: 8.086

Review 3.  The role of chemokines in acute and chronic hepatitis C infection.

Authors:  Stephen Fahey; Eugene Dempsey; Aideen Long
Journal:  Cell Mol Immunol       Date:  2013-08-19       Impact factor: 11.530

4.  Immunogenic properties of a chimeric plant virus expressing a hepatitis C virus (HCV)-derived epitope: new prospects for an HCV vaccine.

Authors:  G Piazzolla; M Nuzzaci; C Tortorella; E Panella; A Natilla; D Boscia; A De Stradis; P Piazzolla; S Antonaci
Journal:  J Clin Immunol       Date:  2005-03       Impact factor: 8.317

5.  Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation.

Authors:  Patrick Lacasse; Jérôme Denis; Réjean Lapointe; Denis Leclerc; Alain Lamarre
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

Review 6.  Pathogenic interactions between alcohol and hepatitis C.

Authors:  Gyongyi Szabo
Journal:  Curr Gastroenterol Rep       Date:  2003-02

7.  Virus genotype 1b and long-term response to interferon alpha monotherapy in children with chronic hepatitis C.

Authors:  Iwona Mozer-Lisewska; Wojciech Słuzewski; Khaled Ali Youseif; Magdalena Figlerowicz; Arleta Kowala-Piaskowska
Journal:  Eur J Pediatr       Date:  2003-08-22       Impact factor: 3.183

Review 8.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

9.  Hepatitis C virus infection in infants and children from Argentina.

Authors:  María Inés Gismondi; Estela Inés Turazza; Saúl Grinstein; María Cristina Galoppo; María Victoria Preciado
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

Review 10.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.